ISSN 1948-9358 (online)

World Journal of *Diabetes*

Monthly Volume 16 Number 1 January 15, 2025

Published by Baishideng Publishing Group Inc

World Journal of Diabetes

Contents

Monthly Volume 16 Number 1 January 15, 2025

EDITORIAL

MINIREVIEWS

ORIGINAL ARTICLE

Retrospective Study

Clinical Trials Study

Prospective Study

World Journal of Diabetes

Monthly Volume 16 Number 1 January 15, 2025

Contents

World Journal of Diabetes

Monthly Volume 16 Number 1 January 15, 2025

Contents

ABOUT COVER

Editorial Board Member of *World Journal of Diabetes*, Maja Cigrovski Berkovic, MD, PhD, Associate Professor, Department of Sport and Exercise Medicine, University of Zagreb Faculty of Kinesiology, Zagreb 10000, Croatia. maja.cigrovskiberkovic@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Diabetes* (*WJD*, *World J Diabetes*) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJD mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

INDEXING/ABSTRACTING

The *WJD* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for *WJD* as 4.2; JIF without journal self cites: 4.1; 5-year JIF: 4.2; JIF Rank: 40/186 in endocrinology and metabolism; JIF Quartile: Q1; and 5-year JIF Quartile: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE

NAME OF JOURNAL
World Journal of Diabetes

ISSN
ISSN 1948-9358 (online)

LAUNCH DATE
June 15, 2010

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Lu Cai, Md. Shahidul Islam, Michael Horowitz

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/1948-9358/editorialboard.htm

PUBLICATION DATE
January 15, 2025

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/GerInfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

World Journal of Diabetes

Submit a Manuscript: https://www.f6publishing.com

World J Diabetes 2025 January 15; 16(1): 98798

DOI: 10.4239/wjd.v16.i1.98798

ISSN 1948-9358 (online)

EDITORIAL

Unveiling mitochondrial mysteries: Exploring novel tRNA variants in type 2 diabetes mellitus

Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng

Specialty type: Endocrinology and metabolism

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification
Scientific Quality: Grade B, Grade B
Novelty: Grade A, Grade B
Creativity or Innovation: Grade A, Grade B
Scientific Significance: Grade B, Grade B

P-Reviewer: Medeiros G; Zhang R

Received: July 5, 2024
Revised: October 21, 2024
Accepted: November 8, 2024
Published online: January 15, 2025
Processing time: 146 Days and 17 Hours

Chun-Han Cheng, Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan

Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei 23561, Taiwan

Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan

Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan

Co-corresponding authors: Wen-Rui Hao and Tzu-Hurng Cheng.

Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw

Abstract

The recent study of Ding *et al* provides valuable insights into the functional implications of novel mitochondrial $tRNA^{Trp}$ and $tRNA^{Ser(AGY)}$ variants in type 2 diabetes mellitus (T2DM). This editorial explores their findings, highlighting the role of mitochondrial dysfunction in the pathogenesis of T2DM. By examining the molecular mechanisms through which these tRNA variants contribute to disease progression, the study introduces new targets for therapeutic strategies. We discuss the broader implications of these results, emphasizing the importance of understanding mitochondrial genetics in addressing T2DM.

Key Words: Mitochondrial tRNA variants; Type 2 diabetes mellitus; Mitochondrial dysfunction; Genetic markers; Therapeutic strategies

Core Tip: This editorial highlights the groundbreaking findings of Ding *et al*, who uncovered novel mitochondrial $tRNA^{Trp}$ and $tRNA^{Ser(AGY)}$ variants associated with type 2 diabetes mellitus (T2DM). By elucidating the functional effects of these variants, the study enhances our understanding of mitochondrial dysfunction in diabetes pathogenesis and suggests new therapeutic targets. Their study underscores the critical role of mitochondrial genetics in developing strategies for managing T2DM.

Citation: Cheng CH, Hao WR, Cheng TH. Unveiling mitochondrial mysteries: Exploring novel tRNA variants in type 2 diabetes mellitus. *World J Diabetes* 2025; 16(1): 98798
URL: https://www.wjgnet.com/1948-9358/full/v16/i1/98798.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i1.98798

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a multifaceted disease characterized by insulin resistance and impaired insulin secretion. Traditionally, research has concentrated on the roles of nuclear genes and environmental factors. However, recent studies have highlighted the significance of mitochondrial dysfunction in the pathogenesis of T2DM. Mitochondria are crucial for cellular energy production and metabolic regulation, and their role in metabolic diseases is becoming increasingly recognized. Variations in mitochondrial DNA (mtDNA), particularly in mitochondrial tRNA genes, have been implicated in altering mitochondrial function and contributing to metabolic disorders[1,2]. The study by Ding *et al* [3] offers an in-depth analysis of the functional impacts of novel mitochondrial $tRNA^{Trp}$ and $tRNA^{Ser(AGY)}$ variants in T2DM patients[3]. This research is a pivotal step in understanding the genetic factors underlying T2DM and underscores the importance of mitochondrial health in maintaining metabolic homeostasis. Sørgjerd *et al*[4] and Yang *et al*[5] have further demonstrated that small RNAs and specific mitochondrial tRNA mutations are differentially expressed in diabetic conditions, linking these genetic variations to the onset and progression of diabetes. The role of mitochondrial dysfunction in diabetes is supported by multiple studies. For example, Song *et al*[6] showed that mesenchymal stromal cells can ameliorate mitochondrial dysfunction in alpha cells[6], highlighting a potential therapeutic approach. Furthermore, García-Peña *et al*[7] discussed the broader implications of mitochondrial dynamics in diabetes and cardiovascular disease, emphasizing the interconnectedness of these metabolic processes. Research by Shukla and Melkani[8] provides additional insights into how mitochondrial dynamics and mtDNA variations can affect cellular metabolism and influence the efficacy of current treatment options, reinforcing the potential for personalized medicine approaches[8]. Camus *et al*[9] also highlight the importance of considering mtDNA variations in the context of disease pathogenesis and treatment[9]. Studies by Diaz-Vegas *et al*[10] and Rönn *et al*[11] further link mitochondrial dysfunction to insulin resistance and β-cell dysfunction, suggesting that therapies targeting mitochondrial health could significantly impact T2DM management. This editorial delves into the implications of the novel mitochondrial $tRNA^{Trp}$ and $tRNA^{Ser(AGY)}$ variants identified by Ding *et al*[3], exploring their potential role in T2DM pathogenesis and their broader impact on future research and therapeutic strategies. Understanding these genetic variations can provide insights into new diagnostic markers and treatment options for T2DM, moving towards a more comprehensive approach to managing this complex disease.

MITOCHONDRIAL DYSFUNCTION IN T2DM

Mitochondria are essential for cellular energy metabolism, playing a pivotal role in ATP production through the electron transport chain. In T2DM, mitochondrial dysfunction has been closely linked to disease development. MtDNA encodes critical components of the electron transport chain, and variations in these genes can impair ATP production and increase reactive oxygen species (ROS) generation, leading to oxidative stress[12,13]. This oxidative stress damages cellular structures, exacerbating insulin resistance and β-cell dysfunction, which are key features of T2DM[2,12-14]. Recent studies have highlighted the significance of mtDNA variations in the pathogenesis of T2DM. Specifically, mutations in mitochondrial tRNA genes, such as $tRNA^{Trp}$ and $tRNA^{Ser(AGY)}$, have been shown to impact mitochondrial function. Ding *et al*[3] investigated the functional consequences of these novel variants in patients with T2DM, revealing their potential role in disease progression[3]. These findings align with previous research indicating that mitochondrial mutations can lead to impaired oxidative phosphorylation and increased ROS production[1,13,15]. Furthermore, mitochondrial dysfunction in T2DM is associated with altered mitochondrial dynamics, including changes in fusion and fission processes. García-Peña *et al*[7] emphasized the importance of mitochondrial dynamics in maintaining cellular homeostasis and how their disruption can contribute to metabolic diseases[7]. This is supported by Diaz-Vegas *et al*[10], who linked mitochondrial electron transport chain dysfunction to insulin resistance in skeletal muscle[10] The implications of these findings are profound, suggesting that targeting mitochondrial health could be a potential therapeutic strategy for T2DM. Understanding how specific mtDNA variants influence mitochondrial function can provide insights into the complex pathophysiology of T2DM and open new avenues for treatment[1,15]. Studies by Camus *et al*[9] and Shukla and Melkani [8] provide additional insights into how mtDNA variations affect cellular metabolism and influence the efficacy of current treatment options, reinforcing the potential for personalized medicine approaches. Future research should focus on elucidating the mechanisms by which mitochondrial dysfunction contributes to T2DM and exploring interventions

that can mitigate these effects. For example, therapeutic approaches that enhance mitochondrial biogenesis or improve mitochondrial efficiency might mitigate the adverse effects of tRNA mutations. Research by Song *et al*[6] indicates that pathways like SIRT1/FoxO3a are pivotal for mitigating mitochondrial dysfunction in diabetic patients, suggesting promising targets for novel therapeutic approaches[6]. Overall, mitochondrial dysfunction plays a crucial role in the pathogenesis of T2DM through impaired ATP production, increased ROS generation, and disrupted mitochondrial dynamics. Investigating mtDNA variations and their impact on mitochondrial function is essential for developing novel therapeutic strategies to combat T2DM[1,2,12-15]. By focusing on these aspects, future research can lead to significant advancements in understanding and treating this complex disease.

NOVEL tRNA^{Trp} AND tRNA$^{Ser(AGY)}$ VARIANTS

The study by Ding *et al*[3] focuses on identifying and characterizing novel variants in mitochondrial *tRNA^{Trp}* and *tRNA$^{Ser(AGY)}$* genes, which are crucial for mitochondrial protein synthesis[3]. Mitochondrial tRNA molecules play an essential role in translating mtDNA into functional proteins necessary for the electron transport chain. Variants in these tRNA genes can disrupt mitochondrial translation, leading to impaired protein synthesis and mitochondrial dysfunction. Ding *et al*[3] utilized advanced molecular techniques to elucidate the effects of these tRNA variants on mitochondrial activity[3]. Their research revealed that the novel *tRNA^{Trp}* and *tRNA$^{Ser(AGY)}$* variants significantly impact mitochondrial protein synthesis and respiratory function. Specifically, these mutations were associated with reduced efficiency in mitochondrial translation and compromised respiratory chain activity, which are critical for ATP production. This study aligns with previous findings indicating that mitochondrial tRNA mutations can lead to mitochondrial dysfunction and contribute to metabolic disorders such as T2DM[5,16]. Moreover, the study by Ding *et al*[3] provides insights into the molecular mechanisms by which these tRNA variants contribute to the pathogenesis of T2DM[3]. The impaired mitochondrial function caused by these mutations can increase oxidative stress, which is known to exacerbate insulin resistance and β-cell dysfunction—hallmarks of T2DM. Understanding these mechanisms is crucial for identifying potential biomarkers for early diagnosis and developing targeted therapies for T2DM. Additionally, other research has highlighted the broader implications of mitochondrial dysfunction in diabetes. For instance, Sørgjerd *et al*[4] demonstrated that small RNAs are differentially expressed in autoimmune and non-autoimmune diabetes, further emphasizing the complexity of mitochondrial involvement in diabetes[4]. This is supported by García-Peña *et al*[7], who discussed the importance of mitochondrial dynamics in maintaining cellular homeostasis and its disruption in metabolic diseases[7]. The identification of novel tRNA^{Trp} and tRNA$^{Ser(AGY)}$ variants by Ding *et al*[3] provides valuable insights into the molecular underpinnings of mitochondrial dysfunction in T2DM[3]. These findings underscore the importance of mitochondrial health in diabetes and highlight potential avenues for therapeutic intervention. Future research should continue to explore the role of mitochondrial genetics in T2DM and investigate strategies to mitigate mitochondrial dysfunction as a means to improve patient outcomes.

PRECISION AND METHODOLOGICAL INNOVATIONS

The study by Ding *et al*[3] stands out for its precision and methodological innovations, particularly in the use of advanced sequencing technologies and bioinformatic tools[3]. This approach enabled a detailed characterization of mitochondrial tRNA variants, essential for understanding their role in T2DM. Techniques such as high-throughput sequencing, mitochondrial functional assays, and comprehensive bioinformatics analyses were crucial in identifying and validating the impact of these tRNA variants on mitochondrial function. High-throughput sequencing facilitated a comprehensive analysis of mitochondrial genomes, leading to the discovery of novel tRNA^{Trp} and tRNA$^{Ser(AGY)}$ variants[3]. Functional assays assessed the impact of these variants on mitochondrial protein synthesis and respiratory chain activity, confirming their role in mitochondrial dysfunction[5]. Additionally, bioinformatics tools predicted the potential pathogenicity of these variants by analyzing their effects on tRNA structure and function[16]. These methodological innovations ensure that the findings can be validated and reproduced in future studies. The rigorous approach taken by Ding *et al*[3] sets a high standard for research in mitochondrial genetics and its association with metabolic diseases[3]. The study not only identifies novel tRNA variants associated with T2DM but also emphasizes the importance of using advanced molecular techniques to uncover the genetic underpinnings of mitochondrial dysfunction[4]. In sum, the research by Ding *et al*[3] highlights the critical role of mitochondrial health in disease pathogenesis and provides a foundation for future studies aimed at developing targeted therapies for metabolic disorders[3]. This is corroborated by other studies which demonstrate the significant impact of mitochondrial tRNA mutations on metabolic health[7,11].

IMPLICATIONS FOR DISEASE PROGRESSION AND MANAGEMENT

The identification of novel mitochondrial tRNA variants by Ding *et al*[3] holds substantial implications for the progression and management of T2DM. The tRNA mutations, particularly in tRNA^{Trp} and tRNA$^{Ser(AGY)}$, significantly impact mitochondrial protein synthesis and respiratory function, leading to compromised ATP production and increased ROS generation. This heightened ROS production results in oxidative stress, which further exacerbates insulin resistance and β-cell dysfunction, central features of T2DM[3]. Detailed analysis of these tRNA variants has shown that they impair

the translation of mitochondrial-encoded proteins, crucial for the electron transport chain's efficiency. For example, mutations in $tRNA^{Trp}$ and $tRNA^{Ser(AGY)}$ can reduce the accuracy and efficiency of mitochondrial translation, leading to the production of defective respiratory chain complexes. This dysfunction hampers ATP production, essential for cellular energy, and increases ROS levels, contributing to oxidative damage and further mitochondrial impairment[4]. The study by Ding *et al*[3] suggests that these mitochondrial dysfunctions, driven by specific tRNA mutations, play a critical role in the pathogenesis of T2DM[3]. The impaired oxidative phosphorylation and elevated ROS levels lead to cellular damage, promoting insulin resistance and β-cell apoptosis. This understanding emphasizes the importance of mitochondrial health in T2DM and highlights the potential of targeting mitochondrial function for therapeutic interventions[5]. Research by García-Peña *et al*[7] supports the idea that restoring mitochondrial dynamics and function could be a viable therapeutic strategy[7]. These studies underline the role of small RNAs and mitochondrial dynamics in maintaining cellular homeostasis and their disruption in metabolic diseases like T2DM. Therapeutic approaches that enhance mitochondrial biogenesis or improve mitochondrial efficiency might mitigate the adverse effects of tRNA mutations[7]. Personalized medicine approaches, incorporating mitochondrial genetics, could revolutionize T2DM management. Understanding how specific mitochondrial tRNA variants affect disease progression can help clinicians predict individual metabolic profiles and treatment responses. For instance, genetic screening for $tRNA^{Trp}$ A5514G and $tRNA^{Ser(AGY)}$ C12237T variants, as highlighted by Yang *et al*[5] and Rahmadanthi and Maksum[16], could identify individuals at higher risk for late-onset T2DM, enabling earlier and more targeted interventions. Furthermore, studies like those by Diaz-Vegas *et al*[10] and Rönn *et al*[11] demonstrate the link between mitochondrial dysfunction and insulin resistance, as well as β-cell dysfunction. Addressing these mitochondrial abnormalities through therapeutic interventions could improve insulin sensitivity and pancreatic function, providing a more comprehensive approach to diabetes management. In addition, recent research by Camus *et al*[9] and Shukla and Melkani[8] provides insights into how mtDNA variations can affect cellular metabolism and influence the efficacy of current treatment options. Understanding these variations could lead to more precise treatment regimens tailored to individual genetic profiles, potentially improving patient outcomes. Overall, the identification of mitochondrial tRNA variants presents significant opportunities for advancing the understanding and treatment of T2DM. By targeting the root causes of metabolic dysfunction through personalized medicine approaches informed by mitochondrial genetics, therapeutic outcomes can be enhanced. Future research should continue to explore these genetic factors and develop interventions aimed at optimizing mitochondrial function to better manage and possibly prevent T2DM. This multifaceted approach could lead to significant strides in combating this prevalent and challenging disease.

FUTURE DIRECTIONS IN MITOCHONDRIAL DIABETES RESEARCH

The study by Ding *et al*[3] introduces promising new avenues for investigating the role of mitochondrial genetics in metabolic diseases, particularlyT2DM[3]. To expand upon these findings, future studies should encompass larger, more diverse cohorts to validate outcomes and assess the prevalence of specific tRNA variants across different populations. This approach will yield a comprehensive understanding of how these genetic mutations impact T2DM[3]. Research into the interplay between mitochondrial and nuclear genomes is crucial for a thorough grasp of T2DM pathogenesis. As highlighted by Sørgjerd *et al*[4], the differential expression of small RNAs in various forms of diabetes suggests that exploring these genomic interactions could offer fresh insights[4]. Moreover, Yang *et al*[5] and Rahmadanthi and Maksum [16] underscore the significance of investigating how specific tRNA mutations, such as $tRNA^{Trp}$ A5514G and $tRNA^{Ser(AGY)}$ C12237T, contribute to the clinical diversity observed in T2DM. The development of therapies targeting mitochondrial dysfunction represents a promising area for innovative treatment strategies. García-Peña *et al*[7] and Diaz-Vegas *et al*[10] demonstrate the potential of restoring mitochondrial function to enhance metabolic health. Targeted therapies that boost mitochondrial biogenesis or function could address critical components of T2DM, including insulin resistance and β-cell dysfunction. Additionally, research by Song *et al*[6] indicates that pathways like SIRT1/FoxO3a are pivotal for mitigating mitochondrial dysfunction in diabetic patients[6]. Understanding these pathways may lead to the creation of targeted therapies that address the fundamental causes of metabolic dysregulation. Furthermore, Camus *et al*[9] provide insights into how mtDNA variations can affect cellular metabolism and influence the efficacy of current treatment options[9]. By understanding these variations, clinicians can tailor treatments to individual genetic profiles, potentially improving patient outcomes. Shukla and Melkani[8] also emphasize the importance of mitochondrial dynamics in maintaining cellular homeostasis, suggesting that therapies aimed at preserving or restoring mitochondrial dynamics could be beneficial for T2DM patients[8]. Additionally, García-Peña *et al*[7] underscore the relevance of mitochondrial dynamics in cardiovascular health, suggesting that integrated treatment strategies could benefit T2DM patients with comorbid conditions. Incorporating mitochondrial health into the broader context of patient care could address multiple aspects of metabolic and cardiovascular health simultaneously[7]. The studies by Bhansali *et al*[17] and Tang *et al*[18] further highlight the importance of mitochondrial quality control and its role in managing metabolic health. Their findings suggest that interventions aimed at enhancing mitochondrial autophagy (mitophagy) could be crucial in maintaining mitochondrial function and reducing the oxidative stress associated with T2DM. Overall, forthcoming research should prioritize large-scale studies to authenticate findings, investigate mitochondrial and nuclear genome interactions, and devise therapies targeting mitochondrial dysfunction. These endeavors hold the potential to revolutionize T2DM treatment by addressing its underlying genetic and metabolic causes. By focusing on the interplay between mtDNA and treatment efficacy, researchers can develop personalized medicine approaches that optimize therapeutic outcomes for T2DM patients. Additionally, integrating mitochondrial health into comprehensive patient care strategies could significantly improve overall metabolic and cardiovascular health, offering a multifaceted approach to managing T2DM

and its complications.

CONCLUSION

The study conducted by Ding *et al*[3] marks a significant advancement in the understanding of the genetic basis of T2DM through the identification of novel mitochondrial $tRNA^{Trp}$ and $tRNA^{Ser(AGY)}$ variants. This research highlights the essential role of mitochondrial health in the pathogenesis of T2DM and opens new avenues for both scientific exploration and therapeutic development. By clarifying the effects of specific mtDNA variations on cellular metabolism, the study provides a deeper insight into disease mechanisms and suggests potential biomarkers and targets for personalized treatment strategies[3]. Future research should focus on validating these findings in larger and more diverse populations to determine the prevalence and impact of these tRNA variants across different ethnicities and environmental contexts. This will help in understanding the genetic diversity in T2DM and its implications for personalized medicine[19]. Moreover, studies that investigate the complex interplay between mitochondrial and nuclear genomes could shed light on the molecular mechanisms driving T2DM[4,5,16]. Developing therapeutic interventions that target mitochondrial dysfunction offers significant promise for transforming T2DM management. Improving mitochondrial function could address key aspects of T2DM, such as insulin resistance and β-cell dysfunction, thereby enhancing patient outcomes[7,10]. Additionally, pathways like SIRT1/FoxO3a have shown potential in mitigating mitochondrial dysfunction in diabetic patients, suggesting promising targets for new therapeutic approaches[6]. Camus *et al*[9] and Shukla and Melkani[8] provide valuable insights into how mtDNA variations can affect cellular metabolism and influence the effectiveness of current treatment options. Understanding these variations allows clinicians to tailor treatments to individual genetic profiles, potentially improving patient outcomes. This aligns with the concept of personalized medicine, where genetic information guides therapeutic decisions. Overall, the work by Ding *et al*[3] represents a pivotal advancement in mitochondrial diabetes research. By identifying and characterizing these novel mitochondrial variants, the study lays the groundwork for further breakthroughs in understanding and treating T2DM. Continued research in this domain, emphasizing genetic validation and the development of targeted therapies, could lead to substantial strides in combating this prevalent and challenging disease. The integration of mitochondrial health into T2DM management strategies has the potential to revolutionize treatment approaches and improve the quality of life for patients. Future studies should also consider the broader implications of mitochondrial dysfunction, such as its impact on cardiovascular health and other metabolic conditions[7]. Addressing mitochondrial dysfunction comprehensively will allow researchers to develop holistic treatment strategies that benefit T2DM patients with comorbid conditions. This approach ensures that advancements in mitochondrial research translate into meaningful clinical outcomes, ultimately transforming the landscape of T2DM management. In conclusion, the exploration of mitochondrial genetics in T2DM offers a promising frontier for research and therapeutic innovation. The findings by Ding *et al*[3] serve as a foundation for future investigations, paving the way for personalized medicine approaches that target the root causes of T2DM[3]. Through continued research and collaboration, the scientific community can unlock new possibilities for understanding, preventing, and treating T2DM, ultimately improving patient outcomes and quality of life.

FOOTNOTES

Author contributions: Cheng CH and Hao WR wrote the paper; Cheng TH revised the paper. All authors have read and approved the final manuscript.

Conflict-of-interest statement: All authors declare that they have no competing interests.

Country of origin: Taiwan

ORCID number: Tzu-Hurng Cheng 0000-0002-9155-4169.

S-Editor: Liu H
L-Editor: A
P-Editor: Xu ZH

REFERENCES

1 **Lowell BB**, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. *Science* 2005; **307**: 384-387 [PMID: 15662004 DOI: 10.1126/science.1104343]

2 **Wallace DC**. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. *Annu*

Rev Genet 2005; **39**: 359-407 [PMID: 16285865 DOI: 10.1146/annurev.genet.39.110304.095751]

3 **Ding Y**, Yu XJ, Guo QX, Leng JH. Functional analysis of the novel mitochondrial tRNA(Trp) and tRNA(Ser(AGY)) variants associated with type 2 diabetes mellitus. *World J Diabetes* 2024; **15**: 1753-1763 [PMID: 39192858 DOI: 10.4239/wjd.v15.i8.1753]

4 **Sørgjerd EP**, Mjelle R, Beisvåg V, Flatberg A, Grill V, Åsvold BO. Small RNAs are differentially expressed in autoimmune and non-autoimmune diabetes and controls. *Eur J Endocrinol* 2022; **187**: 231-240 [PMID: 35616612 DOI: 10.1530/EJE-22-0083]

5 **Yang L**, Guo Q, Leng J, Wang K, Ding Y. Late onset of type 2 diabetes is associated with mitochondrial tRNA(Trp) A5514G and tRNA(Ser(AGY)) C12237T mutations. *J Clin Lab Anal* 2022; **36**: e24102 [PMID: 34811812 DOI: 10.1002/jcla.24102]

6 **Song J**, Wang L, Wang L, Guo X, He Q, Cui C, Hu H, Zang N, Yang M, Yan F, Liang K, Wang C, Liu F, Sun Y, Sun Z, Lai H, Hou X, Chen L. Mesenchymal stromal cells ameliorate mitochondrial dysfunction in α cells and hyperglucagonemia in type 2 diabetes *via* SIRT1/FoxO3a signaling. *Stem Cells Transl Med* 2024; **13**: 776-790 [PMID: 38864709 DOI: 10.1093/stcltm/szae038]

7 **García-Peña LM**, Abel ED, Pereira RO. Mitochondrial Dynamics, Diabetes, and Cardiovascular Disease. *Diabetes* 2024; **73**: 151-161 [PMID: 38241507 DOI: 10.2337/dbi23-0003]

8 **Shukla P**, Melkani GC. Mitochondrial epigenetic modifications and nuclear-mitochondrial communication: A new dimension towards understanding and attenuating the pathogenesis in women with PCOS. *Rev Endocr Metab Disord* 2023; **24**: 317-326 [PMID: 36705802 DOI: 10.1007/s11154-023-09789-2]

9 **Camus MF**, Inwongwan S. Mitonuclear interactions modulate nutritional preference. *Biol Lett* 2023; **19**: 20230375 [PMID: 38053364 DOI: 10.1098/rsbl.2023.0375]

10 **Diaz-Vegas A**, Madsen S, Cooke KC, Carroll L, Khor JXY, Turner N, Lim XY, Astore MA, Morris JC, Don AS, Garfield A, Zarini S, Zemski Berry KA, Ryan AP, Bergman BC, Brozinick JT, James DE, Burchfield JG. Mitochondrial electron transport chain, ceramide, and coenzyme Q are linked in a pathway that drives insulin resistance in skeletal muscle. *Elife* 2023; **12** [PMID: 38149844 DOI: 10.7554/eLife.87340]

11 **Rönn T**, Ofori JK, Perfilyev A, Hamilton A, Pircs K, Eichelmann F, Garcia-Calzon S, Karagiannopoulos A, Stenlund H, Wendt A, Volkov P, Schulze MB, Mulder H, Eliasson L, Ruhrmann S, Bacos K, Ling C. Genes with epigenetic alterations in human pancreatic islets impact mitochondrial function, insulin secretion, and type 2 diabetes. *Nat Commun* 2023; **14**: 8040 [PMID: 38086799 DOI: 10.1038/s41467-023-43719-9]

12 **Ueda S**, Yagi M, Tomoda E, Matsumoto S, Ueyanagi Y, Do Y, Setoyama D, Matsushima Y, Nagao A, Suzuki T, Ide T, Mori Y, Oyama N, Kang D, Uchiumi T. Mitochondrial haplotype mutation alleviates respiratory defect of MELAS by restoring taurine modification in tRNA with 3243A>G mutation. *Nucleic Acids Res* 2023; **51**: 7480-7495 [PMID: 37439353 DOI: 10.1093/nar/gkad591]

13 **Wang B**, Shi D, Yang S, Lian Y, Li H, Cao M, He Y, Zhang L, Qiu C, Liu T, Wen W, Ma Y, Shi L, Cheng T, Shi L, Yuan W, Chu Y, Shi J. Mitochondrial tRNA pseudouridylation governs erythropoiesis. *Blood* 2024; **144**: 657-671 [PMID: 38635773 DOI: 10.1182/blood.2023022004]

14 **Maechler P**, Wollheim CB. Mitochondrial function in normal and diabetic beta-cells. *Nature* 2001; **414**: 807-812 [PMID: 11742413 DOI: 10.1038/414807a]

15 **Petersen KF**, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. *Science* 2003; **300**: 1140-1142 [PMID: 12750520 DOI: 10.1126/science.1082889]

16 **Rahmadanthi FR**, Maksum IP. Transfer RNA Mutation Associated with Type 2 Diabetes Mellitus. *Biology (Basel)* 2023; **12** [PMID: 37372155 DOI: 10.3390/biology12060871]

17 **Bhansali S**, Bhansali A, Dutta P, Walia R, Dhawan V. Metformin upregulates mitophagy in patients with T2DM: A randomized placebo-controlled study. *J Cell Mol Med* 2020; **24**: 2832-2846 [PMID: 31975558 DOI: 10.1111/jcmm.14834]

18 **Tang W**, Yan C, He S, Du M, Cheng B, Deng B, Zhu S, Li Y, Wang Q. Neuron-targeted overexpression of caveolin-1 alleviates diabetes-associated cognitive dysfunction *via* regulating mitochondrial fission-mitophagy axis. *Cell Commun Signal* 2023; **21**: 357 [PMID: 38102662 DOI: 10.1186/s12964-023-01328-5]

19 **Lin L**, Zhang D, Jin Q, Teng Y, Yao X, Zhao T, Xu X, Jin Y. Mutational Analysis of Mitochondrial tRNA Genes in 200 Patients with Type 2 Diabetes Mellitus. *Int J Gen Med* 2021; **14**: 5719-5735 [PMID: 34557026 DOI: 10.2147/IJGM.S330973]

Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: office@baishideng.com
Help Desk: https://www.f6publishing.com/helpdesk
https://www.wjgnet.com